Aldeyra Therapeutics, Inc.
ALDX
$1.71
-$0.05-2.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 52.56% | 39.40% | 3.58% | -33.67% | -92.27% |
| Total Depreciation and Amortization | 3.12% | 0.96% | -0.16% | -1.22% | -2.54% |
| Total Amortization of Deferred Charges | -100.00% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -66.20% | -20.36% | -0.05% | 74.29% | 112.16% |
| Change in Net Operating Assets | -126.71% | -187.57% | -125.81% | -2.27% | 204.18% |
| Cash from Operations | 43.14% | 22.83% | -30.69% | -33.58% | -48.13% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 657.97% | 206.28% | 169.60% | 121.46% | 76.14% |
| Cash from Investing | 657.97% | 206.28% | 169.60% | 121.46% | 76.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 71.94% | 71.94% | 71.94% |
| Issuance of Common Stock | -86.03% | 189.26% | 2,057.83% | 416.94% | 406.83% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 76.99% | -- | -- |
| Cash from Financing | -76.41% | 755.48% | 194.95% | 162.08% | 162.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 128.10% | 117.57% | 88.33% | 63.06% | 16.62% |